What’s Next for Weight Loss Drug Marketing?
The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.
Top executives from drugmakers big and small told CNBC that the next phase of the space will be defined by a broader range of treatment options and improved access for patients. Those were among the themes that emerged at the annual JPMorgan Healthcare Conference in San Francisco during interviews with top brass from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers.
“We really see the obesity market going from, in this year, a one-size-fits-all kind of idea to different medicines for different patients. We don’t have a crystal ball to know how that all sorts out,” Dan Skovronsky, Eli Lilly’s chief scientific officer, told CNBC in an interview at the conference.
Excerpted from CNBC
